LXEO
Lexeo Therapeutics, Inc.
Set alert
- YTD
- -68.38%
- 1 year
- -66.70%
- Open
- 3.10
- Prev close
- 3.06
- Mkt cap
- 257.76M
- Vol
- 1.00M
- Avg vol
- 1.30M
- EPS
- -1.02
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.90
- High
- 3.30
- Forward P/E
- -2.24
- Beta
- 0.00
- Short ratio
- 6.55
- Inst. own
- 91.48%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 9, 2024
- 50-d avg
- 7.92
- 200-d avg
- 11.86
- 1y target
- 22.29
Key statistics
- Market cap
- 205.41M
- Enterprise value
- 90.11M
- Trailing P/E
- 0.00
- Forward P/E
- -2.24
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.46
- EPS (TTM)
- -12.64
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -36.83M
- Total cash
- 174.98M
- Total debt
- 10.85M
- Return on equity
- -74.83%
- Shares outstanding
- 33.08M
- Short % of float
- 7.42%
- 50-day average
- 7.92
- 200-day average
- 11.86
Analyst view
Consensus: none
- Target (low)
- 16.00
- Target (mean)
- 22.29
- Target (high)
- 28.00
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 9, 2024
Expected May 9, 2024. Consensus EPS estimate -0.77664.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.65 | -0.89 | -0.24 | -36.92% |
| May 9, 2024 | Mar 1, 2024 | -0.76 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.76 | -0.77 | -0.01 | -1.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 13, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 13, 2024 | Leerink Partners | main | Outperform | Outperform |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 30, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 25, 2024 | Chardan Capital | main | Buy | Buy |
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lexeotx.com
News
- Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
- Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
- Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript
- Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
- Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
- Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)
- Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
- Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
- Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
- Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Your note
Sign in to keep a note on LXEO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADLER ERIC | Officer | Stock Award(Grant) | Feb 1, 2024 | 26,875 |
| CHOLMONDELEY PAULA H. J. | Director | Purchase | Nov 24, 2024 | 30,627 |
| LONGITUDE CAPITAL PARTNERS IV, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 6, 2023 | 0 |
| LUNDBECKFOND INVEST AS | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 6, 2023 | 1,835,960 |
| MCCORMAC PAUL | Chief Technology Officer | Conversion of Exercise of derivative security | Nov 6, 2023 | 17,349 |
| OMEGA FUND VI, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 6, 2023 | 2,157,620 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 11.38% | 3,763,195 | 23.37M | Sep 29, 2024 |
| Citadel Advisors Llc | 8.24% | 2,723,363 | 16.91M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 7.86% | 2,597,736 | 16.13M | Sep 29, 2024 |
| D1 Capital Partners, LP | 7.58% | 2,506,607 | 15.57M | Sep 29, 2024 |
| Omega Fund Management, Llc | 7.12% | 2,355,904 | 14.63M | Sep 29, 2024 |
| Eventide Asset Management LLC | 5.61% | 1,855,986 | 11.53M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 4.61% | 1,525,517 | 9.47M | Sep 29, 2024 |
| Janus Henderson Global Life Sciences Fund | 2.21% | 731,182 | 4.54M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.80% | 595,877 | 3.70M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.22% | 404,869 | 2.51M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.82% | 272,700 | 1.69M | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.59% | 194,828 | 1.21M | Oct 30, 2024 |